Dyno Therapeutics jobs

Sr. Research Associate, Vector Production Watertown, Massachusetts, United States The Role Senior Research Associate, Vector Production. Hands-on lab role supporting reliable AAV manufacturing and process development through execution of upstream, downstream, and QC-support workflows, with strong emphasis on operational rigor. Job Type: Full Time, onsite Location: Watertown, MA How You Will Contribute As Senior Research Associate, Vector Production, you will be responsible for executing AAV manufacturing and process-development lab work across upstream, downstream, and QC-support workflows while maintaining strong documentation, sample handling, and operational discipline. At Dyno, every role is mission-driven. Whether in science, engineering, operations, or business, each AAViator contributes to solving some of the most complex challenges in genetic medicine. Responsibilities: - Execute AAV upstream, downstream, and QC-support workflows in support of team production and development priorities - Maintain accurate, timely documentation in lab notebooks and operational tracking systems - Support process development experiments through careful execution, troubleshooting, and data capture - Contribute to shared lab operations, including sample handling, inventory, and SOP updates - Partner closely with team members to coordinate work, surface issues early, and maintain execution quality - Work with urgency and adaptability, balancing innovation with execution. - Collaborate cross-functionally, leveraging Dyno's high-trust, high-impact culture to drive results. Basic qualifications - Bachelor's degree in biology, biochemistry, bioengineering, chemical engineering, molecular biology, or related field - 4+ years of relevant lab experience - Direct hands-on experience with AAV production in a research, biotech, or process-development setting - Hands-on experience with mammalian cell culture and aseptic technique

Software Engineer II, Computational Platform Remote; Watertown, Massachusetts, United States The Role Software Engineer II A collaborative full-stack and cloud engineer who thrives at the intersection of software craftsmanship and cutting-edge AI. This role is for someone eager to build and scale the external-facing AI products that put Dyno's breakthrough genetic medicine capabilities in the hands of scientists and partners around the world. Job Type: Full Time Location: Watertown, MA or Remote How You Will Contribute As a Software Engineer II, you will be responsible for building and maintaining Dyno's internal and external-facing AI products. You will drive development of the cloud infrastructure that makes them reliable, scalable, and secure. You will implement novel tooling that empowers Dyno's scientists and external partners to work at the frontier of AI-driven genetic medicine. At Dyno, every role is mission-driven. Whether in science, engineering, operations, or business, each AAViator contributes to solving some of the most complex challenges in genetic medicine. Responsibilities: - Drive engineering quality and reliability of Dyno's external-facing AI products such as design.dynotx.com. - Enable scaling of AI product workflows on design.dynotx.com to handle thousands of simultaneous workflows. - Translate scientific and clinical questions into production-ready systems, including APIs, pipelines, and user-facing tools - Implement a sound data platform for generation, processing, and serving AI data, ensuring access, security, and data lifecycle integrity. - Move quickly from prototype to production, balancing speed with reliability. - Work with urgency and adaptability, balancing innovation with execution. - Collaborate cross-functionally, leveraging Dyno's high-trust,

Scientist I, Immune Evasion Watertown, Massachusetts, United States The Role Scientist I, Immune Evasion. Advancing Dyno's immune evasion capabilities by developing and executing innovative assay strategies that enable the discovery and clinical readiness of next-generation capsids. Job Type: Full Time, onsite Location: Watertown, MA How You Will Contribute As a Scientist I, you will independently lead and evolve Dyno's high-throughput immune evasion assay platform, driving antibody evasion studies that support CNS and Muscle capsid discovery programs and partnering cross-functionally to shape experimental strategy and address technical gaps. You will also help expand the team's immune evasion capabilities beyond pre-existing antibodies to emerging clinical readiness challenges, including re-dosing, T-cell responses, complement activation, and innate immunity. At Dyno, every role is mission-driven. Whether in science, engineering, operations, or business, each AAViator contributes to solving some of the most complex challenges in genetic medicine. Responsibilities: - Independently execute and support high-throughput immune evasion (IE) assays, including antibody neutralization and total antibody immunoprecipitation (tAb IP) workflows, to ensure uninterrupted support for CNS and Muscle capsid discovery programs. - Own the day-to-day operation, optimization, and troubleshooting of immune evasion assay platforms, iteratively refining workflows and developing new assay formats in response to evolving program needs and emerging data. - Analyze, interpret, and communicate immune evasion screening data to cross-functional stakeholders, helping inform capsid selection and discovery strategy. - Contribute to the expansion of Dyno's immune evasion capabilities beyond antibody neutralization by reviewing literature, proposing experimental approaches, and conducting feasibility studies related to re-dosing, T-cell responses,

Director, Ecosystem Development + Communications Watertown, Massachusetts, United States The Role Director, Ecosystem Development & Communications . A systems-minded ecosystem builder who knows how to turn vision into durable infrastructure, scaling communities, flagship convenings, and strategic partnerships into high-impact platforms. This role is for a leader eager to expand the genetic agency movement, amplifying Dyno's influence while growing a sustainable, science-forward ecosystem at the forefront of gene therapy. Job Type: Full Time Location: Watertown, MA How You Will Contribute As Director, Ecosystem Development & Communications you will be responsible for building and scaling the movement of genetic agency, an individual's ability to take action at the genetic level to live a healthier life , and GATC ( see highlights from our inaugural GATC) into a sustainable, high-impact, “can't miss” series of convenings and community infrastructure. You will also integrate and execute Dyno's external communications across partnerships, executives, and strategic initiatives to amplify impact. At Dyno, every role is mission-driven. Whether in science, engineering, operations, or business, each AAViator contributes to solving some of the most complex challenges in genetic medicine. Responsibilities: - Lead and execute Dyno's genetic agency ecosystem strategy, translating vision into structured programming and measurable growth. - Scale GATC into a high-impact, fiscally sustainable event series with increasing participation, repeat attendance, and diversity of organizations. - Design and deliver participatory ecosystem experiences that create meaningful engagement and long-term community retention. - Partner with Dyno executives to embed company priorities into ecosystem initiatives and external programming. - Build and

Medical Science Liaison - West Field-Based Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ , and follow us on X , LinkedIn and Facebook . Role Summary: The Medical Science Liaison (MSL) is an experienced field medical expert who plays a strategic role on the field medical team with depth and breadth of business acumen, therapeutic knowledge and serves as an informal leader on the team. The person in this role is a customer facing , field-based extension of our Medical Affairs team. The MSL's key objective is to create impact through advancing clinical practice within the assigned territory that leads to improved patient outcomes. This individual serves as a key scientific resource, engaging with healthcare professionals (HCPs), key opinion leaders (KOLs), and other stakeholders to provide scientific and clinical support for our portfolio. This is a field-based role. Primary Responsibilities Include : Builds awareness of the company within the medical community and develops strategic KOL/territory engagement plans aligned with the medical strategy Supports clinical research (investigator-initiated and company-sponsored),

Associate Director, Statistical Programming Waltham, MA Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ , and follow us on X , LinkedIn and Facebook . Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Role Summary: The Associate Director, Statistical Programming is accountable for program-specific and cross-study statistical programming activities, including oversight of vendor programming activities. In collaboration with cross-functional stakeholders, this position contributes to process optimization, innovation, and consistency across studies. This position provides technical leadership for statistical programming activities across multiple studies within a program, including oversight of vendor-related activities and implementation of data

Associate Director, Formulation and Drug Product Development Waltham, MA Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ , and follow us on X , LinkedIn and Facebook . Role Summary: The Associate Director, Formulation and Drug Product Development will be accountable for all internal and external activities related to successful formulation development for Dyne's bioconjugate drug products to ensure favorable manufacturability, product quality, and long-term stability. This role will partner closely with colleagues in Research, Pharmaceutical Quality, and Manufacturing to define Dyne's strategy for bringing best-in-class medicines to patients in need, including high-concentration formulations for subcutaneous administration and lyophilized drug products to ensure seamless supply of all drug products for clinical trials. This role is based in Waltham, MA without the possibility of being a remote role. Physical presence onsite is expected on 4-5 days/week. Primary Responsibilities Include: Act as the subject matter expert for drug product development within the Technical Development group, including formulation development, selection of container closure systems, and sterile fill finish clinical manufacturing. Act as

Associate Director, Oligonucleotide Development Waltham, MA Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ , and follow us on X , LinkedIn and Facebook . Role Summary: The Associate Director, Oligonucleotide Development will lead the chemical synthesis strategy for PMO and ASO payload molecules, managing execution both internally and across global CDMOs. This role spans the full development lifecycle - from preclinical process and analytical development through GMP manufacture for IND-enabling studies. The role will ensure the delivery of robust, scalable, and cost-effective manufacturing processes, serve as the primary technical lead for external CDMOs, driving aggressive timelines while delivering well-characterized products optimized for our proprietary bioconjugation platform. As a core member of multiple CMC teams, the Associate Director of Oligonucleotide Development will steer the development of preclinical assets and define CMC strategies within a matrixed environment. The role will play a critical role in global regulatory filings (IND, IMPD, etc.) by authoring and reviewing key Module 3 sections. This role is based in Waltham, MA without the possibility of

Director, Business & Operations – US Commercial Waltham, MA Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ , and follow us on X , LinkedIn and Facebook . Role Summary: The Director, Business & Operations - US Affiliate will serve as a key strategic and operational partner to the SVP, Head of US Affiliate, supporting the effectiveness, execution, and scalability of the US Affiliate organization. This role will provide operational leadership and continuity across the function, enabling the US Affiliate & Commercial Leadership Team to remain focused on the highest‑impact priorities as Dyne builds and grows its US presence. The Director will be responsible for business operations across the US Affiliate, including budget ownership and financial planning, vendor and contract management, operating rhythm and governance, and the execution of function‑wide initiatives. Acting as a connective hub across Commercial, Medical, Finance, Legal, HR, and other G&A partners, this leader will translate strategic priorities into well‑structured plans, drive execution, and ensure visibility into progress, risks, and resource needs. The ideal candidate

Director, Patient Advocacy and Operations Waltham, MA Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ , and follow us on X , LinkedIn and Facebook . Role Summary: The Director, Patient Advocacy & Operations works as part of the Corporate & Patient Affairs (C&PA) team with two key areas of focus: 1) Cultivating and supporting strategic partnerships with patient advocacy organizations and 2) day-to-day management of key Patient Advocacy and Corporate Affairs operations. Reporting to the VP, Patient Advocacy, this role is highly integrated with internal cross-functional teams and partners with external organizations. This role is based in Waltham, MA and does not offer a remote option. Primary Responsibilities include: In collaboration with the VP of Patient Advocacy, partner closely with advocacy leaders and the broader patient community to advance key initiatives, including but not limited to: Executing the patient advocacy strategy in alignment with corporate objectives Fostering strong, strategic relationships with patient leaders, caregivers, and advocacy organizations to inform company programs and priorities. Leading the planning and management

Associate Director, Commercial Insights and Analytics Waltham, MA Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ , and follow us on X , LinkedIn and Facebook . Role Summary : The Associate Director, Commercial Insights and Analytics is responsible for driving the development and execution of market insights to support commercial preparation for Dyne's first product launches in rare neuromuscular diseases. Key areas of focus include data analytics and reporting, forecasting, market research, and competitive intelligence. This individual, who reports directly into the Senior Director, Insights and Analytics, also works closely with many other functions, including but not limited to, marketing, market access, and program teams to support insights generation that will drive brand strategy and execution. This role is based in Waltham, MA. Primary Responsibilities Include: Commercial Data Analytics and Reporting Build and maintain reporting systems using tools like Tableau, Power BI, etc. Partner with IT/Data teams to ensure data integrity and integration across platforms (CRM, claims, EMR, etc.) Standardize reporting templates for executive, field, and cross-functional use

Director, Imaging Biomarkers Waltham, MA Company Overview: Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. We are developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. The company is advancing clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as a preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities. Learn more at https://www.dyne-tx.com/ , and follow us on X , LinkedIn and Facebook . Role Summary: The Director of Imaging Biomarkers lead s the development and execution of innovative imaging strategies across Dyne's therapeutic programs. This pivotal role will ensur e that imaging biomarker strategies are scientifically rigorous, clinically relevant, and condu cive to robust therapeutic development. The person in this role focuses on enhancing the understanding of disease mechanisms , patient populations, evaluating therapeutic efficacy, and supporting clinical trial designs through innovative imaging approaches. This role is cri tical to linking early phase research to clinical development, providing essential insights that drive decision making. The person in this role leverages their expertise in various imaging modalities to develop novel biomarker applications that assess therapeutic efficacy, drive patient-centric trial designs, and facilitate regulatory approval processes. This role combines scientific depth with strategic vision, driving the discovery, validation, and application of advanced imaging modalities to enable precision medicine and accelerate

Production Tech - Dyno 1894 Newnan, GA - GPS posted: Posted 30+ Days Ago

Drug Safety Manager Viking Therapeutics, Inc. Drug Safety Manager

Clinical Trial Manager Viking Therapeutics, Inc. Clinical Trial Manager

Senior Clinical Trial Associate (CONTRACT) Boston, MA The Organization What's happening at Entrada Therapeutics? Entrada is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. Through proprietary and versatile approaches, Entrada is advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. Our lead oligonucleotide programs are in development for the potential treatment of people living with Duchenne muscular dystrophy (DMD) who are exon 44, 45, 50 and 51 skipping amenable. Entrada has partnered with Vertex Pharmaceuticals to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1 (DM1). 2026 represents a catalyst-rich period for Entrada. We expect multiple clinical data readouts as we advance several DMD programs across the U.K., EU, and U.S. By year-end 2026, we anticipate four clinical-stage programs in our DMD franchise (ENTR-601-44, ENTR-601-45, ENTR-601-50, and ENTR-601-51). These programs are complemented by the ongoing clinical progress of our DM1 collaboration with Vertex (VX-670). We are a tight-knit team of experts and leaders in both therapeutic development and rare diseases and are excited to grow and attract colleagues who are ready to join a high-energy, dedicated team that likes to get things done and dramatically improve the lives of patients and their families. The Perfect Addition to Our Team You are patient focused and excited about the opportunity to help support and develop the Clinical Operations organization at

Associate Director, Formulation Development Viking Therapeutics, Inc. Associate Director, Formulation Development

Senior/Executive Director, Health Economics & Outcomes Research (HEOR) Viking Therapeutics, Inc. Senior/Executive Director, Health Economics & Outcomes Research (HEOR)

Director of Process Validation Viking Therapeutics, Inc. Director of Process Validation

Medical Science Liaison Director/Lead Viking Therapeutics, Inc. Medical Science Liaison Director/Lead

Associate Director, Clinical Development Remote Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Our lead product candidate, lysergide tartrate (our proprietary orally disintegrating tablet form of lysergide (LSD) D-tartrate), represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges. Guided by the recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today's mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX. Together we are moving psychiatry forward-beyond better, into a boundless future. Join us! The Associate Director, Clinical Development plays a key role in the design and execution of ongoing and new clinical development studies. This position serves as the clinical science representative on one or more U.S. and/or global clinical studies and contributes to the delivery of high‑quality clinical data to support registration and launch. The role partners cross‑functionally with Clinical Operations, Clinical Pharmacology, Regulatory Affairs, Early Development,

Senior Director, Clinical Development Remote Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Our lead product candidate, lysergide tartrate (our proprietary orally disintegrating tablet form of lysergide (LSD) D-tartrate), represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges. Guided by the recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today's mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX. Together we are moving psychiatry forward-beyond better, into a boundless future. Join us! The Sr. Director, Clinical Development will play a key role in the design and execution of ongoing and new clinical studies and contribute to the clinical development plan for one or more programs. The position will successfully lead and/or serve as the clinical science representative on one or more clinical studies (US and/or global) to deliver high quality data for registration. The position requires the

Vice President, Commercial Manufacturing Operations Remote Vera Therapeutics is a biotechnology company focused on developing treatments for serious immunological diseases. Vera Therapeutics' mission is to advance treatments that target the source of disease in order to change the standard of care for patients. Vera Therapeutics' lead product candidate is atacicept, a fusion protein self-administered at home as a subcutaneous once weekly injection that blocks both B-cell Activating Factor (BAFF) and A Proliferation-Inducing Ligand (APRIL), which stimulate B cells to produce autoantibodies contributing to certain autoimmune diseases, including IgA nephropathy (IgAN) and lupus nephritis. Beyond IgAN, Vera Therapeutics is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove clinically meaningful. In addition, Vera Therapeutics holds an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B-cell-mediated diseases. Vera Therapeutics is also evaluating the development of MAU868, a monoclonal antibody designed to neutralize infection with BK virus, which can have devastating consequences in kidney transplant recipients. Vera Therapeutics retains all global developmental and commercial rights to atacicept, VT-109, and MAU868. For more information, please visit www.veratx.com . Our values are the cornerstone of our culture. Our values inspire us every day and guide everything we do-from how we hire great people, to advancing our mission together, to achieving our ultimate goal to improve medical treatment for patients suffering from immunological diseases. Position Summary: The Vice President, Manufacturing Operations will report

Senior Director, Marketing Remote Definium Therapeutics is a late-stage clinical biopharmaceutical company and our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. Our lead product candidate, lysergide tartrate (our proprietary orally disintegrating tablet form of lysergide (LSD) D-tartrate), represents a highly differentiated, potential best-in-class opportunity for patients suffering from generalized anxiety, major depressive disorder, and posttraumatic stress disorder. Our early stage pipeline includes DT402, the R-enantiomer of MDMA and is under development to target the core symptoms of autism spectrum disorder (ASD), specifically addressing social communication challenges. Guided by the recognition that patients deserve more than better, Definium is relentlessly advancing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders. By turning evidence into impact, Definium aims to change the trajectory of today's mental health care crisis and enable a healthier future. Headquartered in New York, Definium Therapeutics trades on Nasdaq under the symbol DFTX. Together we are moving psychiatry forward-beyond better, into a boundless future. Join us! Definium Therapeutics, formerly known as Mind Medicine, is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key